AU2010310515B2 - Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment - Google Patents

Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment Download PDF

Info

Publication number
AU2010310515B2
AU2010310515B2 AU2010310515A AU2010310515A AU2010310515B2 AU 2010310515 B2 AU2010310515 B2 AU 2010310515B2 AU 2010310515 A AU2010310515 A AU 2010310515A AU 2010310515 A AU2010310515 A AU 2010310515A AU 2010310515 B2 AU2010310515 B2 AU 2010310515B2
Authority
AU
Australia
Prior art keywords
patient
diet
cancer
chemotherapy
predetermined period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010310515A
Other languages
English (en)
Other versions
AU2010310515A1 (en
Inventor
Changhan Lee
Valter D. Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2010310515A1 publication Critical patent/AU2010310515A1/en
Application granted granted Critical
Publication of AU2010310515B2 publication Critical patent/AU2010310515B2/en
Priority to AU2016201607A priority Critical patent/AU2016201607B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Economics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2010310515A 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment Active AU2010310515B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016201607A AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
US61/254,154 2009-10-22
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016201607A Division AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (2)

Publication Number Publication Date
AU2010310515A1 AU2010310515A1 (en) 2012-05-17
AU2010310515B2 true AU2010310515B2 (en) 2016-01-07

Family

ID=43900993

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2010310515A Active AU2010310515B2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
AU2016201607A Active AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016201607A Active AU2016201607B2 (en) 2009-10-22 2016-03-11 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Country Status (13)

Country Link
US (2) US20110118528A1 (enExample)
EP (1) EP2490684B1 (enExample)
JP (1) JP2013508411A (enExample)
CN (1) CN102753162A (enExample)
AU (2) AU2010310515B2 (enExample)
BR (1) BR112012009423A2 (enExample)
CA (1) CA2779282C (enExample)
DK (1) DK2490684T3 (enExample)
ES (1) ES2659353T3 (enExample)
PL (1) PL2490684T3 (enExample)
PT (1) PT2490684T (enExample)
RU (1) RU2549954C2 (enExample)
WO (1) WO2011050302A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822178T3 (es) * 2012-10-22 2021-04-29 Univ Southern California Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
NZ715431A (en) 2013-07-01 2022-02-25 Univ Southern California Fasting condition as dietary treatment of diabetes
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
US10117872B2 (en) * 2014-03-28 2018-11-06 Università Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
MX2016012896A (es) * 2014-04-02 2017-05-12 Univ Southern California Autoinmunidad y tratamiento de la esclerosis multiple.
CA3108664A1 (en) * 2015-04-16 2016-10-20 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
CA2984891A1 (en) 2015-05-06 2016-11-10 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
AU2016328683A1 (en) * 2015-09-21 2018-05-10 Ifom Fondazione Istituto Firc Di Oncologia Molecolare New therapeutic strategies against blood cancer
AU2017207370B2 (en) * 2016-01-12 2021-09-23 University Of Southern California Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
AU2017219732B2 (en) 2016-02-15 2022-01-20 University Of Southern California Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
CN109069462A (zh) 2016-02-23 2018-12-21 癌症研究科技有限公司 缺乏至少两种非必需氨基酸的膳食产品
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
KR20200125966A (ko) 2018-03-15 2020-11-05 유니버시티 오브 써던 캘리포니아 염증 및 ibd 병리의 역전을 촉진하는, 물만 섭취하는 금식이 아닌 금식 모방 식이요법 (fmd)
DE212018000421U1 (de) * 2018-07-18 2021-03-01 Andreas Michalsen Auswirkungen einer kurzzeitigen Diät, die Fasten imitiert, auf die Lebensqualität und die Verträglichkeit einer Chemotherapie bei Patientinnen mit Krebs
AU2019376681B2 (en) 2018-11-09 2025-07-24 L-Nutra Inc. Nutrition bar for intermittent fasting-mimicking
US12185747B2 (en) 2019-04-30 2025-01-07 University Of Southern California Fasting-mimicking diet (FMD) as an intervention for Alzheimer's disease (AD)
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
KR20220098682A (ko) * 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
WO2021118324A1 (ko) * 2019-12-13 2021-06-17 서울대학교산학협력단 암의 예방 또는 치료용 약학 조성물
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
JP2023530235A (ja) 2020-06-03 2023-07-14 フェス・セラピューティクス，インコーポレーテッド 個別化された処置方法のための製剤
CN116133653A (zh) 2020-06-04 2023-05-16 菲思治疗公司 治疗癌症的个体化方法
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
US20240000125A1 (en) * 2020-12-17 2024-01-04 Fondazione Irccs Istituto Nazionale Dei Tumori Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823B1 (en) 2021-03-30 2025-04-30 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Reduced caloric intake and anticancer agents for the treatment of cancer
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学（Cn） 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
EP4599826A1 (en) 2024-02-06 2025-08-13 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Leucine for use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070378A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
RU2224510C2 (ru) * 1997-03-17 2004-02-27 Би Ти Джи Интернэшнл Лимитед Терапевтические композиции
AU5319499A (en) * 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
AU2005296271A1 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
ES2891733T3 (es) * 2007-03-28 2022-01-31 Univ Southern California Inducción de la resistencia diferencial al estrés y usos de la misma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070378A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BYERS T, et al. CA A Cancer Journal for Clinicians, (2002) Vol 52 pp 92-119 *
FOLADOR A, et al. Int J Cancer, (2006) Vol 120, pp 344-350. *
KLURFELD et al. Cancer Research, (1987) Vol 47, pp 2759-2762. *
MIZUSHIMA N, et al. Nature, (2008) Vol 451(7182) pp 1069-1075. *
RAFFAGHELLO L, et al. PNAS, (2008) Vol 105 No 24 pp 8215-8220. *

Also Published As

Publication number Publication date
US20110118528A1 (en) 2011-05-19
CN102753162A (zh) 2012-10-24
PL2490684T3 (pl) 2018-07-31
EP2490684A2 (en) 2012-08-29
RU2549954C2 (ru) 2015-05-10
AU2016201607B2 (en) 2017-11-30
PT2490684T (pt) 2018-04-02
WO2011050302A2 (en) 2011-04-28
EP2490684B1 (en) 2018-01-03
BR112012009423A2 (pt) 2017-06-13
US20210209516A1 (en) 2021-07-08
CA2779282C (en) 2017-12-05
RU2012118588A (ru) 2013-11-27
AU2010310515A1 (en) 2012-05-17
ES2659353T3 (es) 2018-03-14
CA2779282A1 (en) 2011-04-28
AU2016201607A1 (en) 2016-03-31
DK2490684T3 (en) 2018-04-09
EP2490684A4 (en) 2016-05-04
WO2011050302A3 (en) 2011-08-25
JP2013508411A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
US20210209516A1 (en) Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
Arends et al. ESPEN guidelines on enteral nutrition: non-surgical oncology
JP7038432B2 (ja) 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
Morland et al. n-3 polyunsaturated fatty acid supplementation during cancer chemotherapy
US10172839B2 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
RU2734774C2 (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
JP2021101721A (ja) 癌における食事療法の開発
US10905725B2 (en) Compositions and methods for enhancing cancer chemotherapy
WO2018170457A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
HK1258621A1 (zh) 长期禁食模仿作为多发性骨髓瘤和其他癌症的膳食治疗的用途
US20240358769A1 (en) Compositions and Methods for Treating Inflammation Associated with IL-6
WO2025168693A1 (en) Leucine for use in the treatment of cancer
HK1233488B (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
Bussink The role of nutrition on effectiveness of chemotherapy
Tan Why Do Cancer Patients Take More Vitamins?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)